Basic
For individual researchers
$2,499per seat / year
Choose BasicBOIN, CRM, BLRM and BLRM-Comb for dose finding. The Bayesian optimal design for binary endpoints, Simon two-stage and Bayesian monitoring for phase II.
Every plan opens the full Design Hub. Your plan decides which designs you can run.
Prices are in US dollars, per seat, billed yearly.
For individual researchers
$2,499per seat / year
Choose BasicBOIN, CRM, BLRM and BLRM-Comb for dose finding. The Bayesian optimal design for binary endpoints, Simon two-stage and Bayesian monitoring for phase II.
Recommended
For active design teams
$4,999per seat / year
Choose ProfessionalEverything in Basic, plus every BOIN and CRM variant, every Bayesian optimal design endpoint and rBOP2. Unlimited simulations and priority support.
For pharma and CROs
$7,999per seat / year
Choose ExpertEverything in Professional, plus information borrowing and KM curve reconstruction. Unlimited users.
| Design | Basic$2,499 | Professional$4,999 | Expert$7,999 |
|---|---|---|---|
| Phase IDose finding | |||
| BOINSingle agent | Included | Included | Included |
| CRMSingle agent | Included | Included | Included |
| BLRMSingle agent | Included | Included | Included |
| BLRM-CombDrug combination | Included | Included | Included |
| BMA-CRMModel averaging | Not included | Included | Included |
| BOIN-CombDrug combination | Not included | Included | Included |
| TITE-BOINLate-onset toxicity | Not included | Included | Included |
| TITE-CRMLate-onset toxicity | Not included | Included | Included |
| BOIN12Optimal biological dose | Not included | Included | Included |
| BF-BOINBackfill cohorts | Not included | Included | Included |
| Phase IIEfficacy screening | |||
| Bayesian optimal design for binary endpoints | Included | Included | Included |
| Simon two-stageSingle arm | Included | Included | Included |
| Bayesian toxicity monitoring | Included | Included | Included |
| Bayesian efficacy monitoringPosterior probability | Included | Included | Included |
| Bayesian efficacy monitoringPredictive probability | Included | Included | Included |
| Bayesian optimal design for toxicity endpoints | Not included | Included | Included |
| Bayesian optimal design for joint efficacy and toxicity endpoints | Not included | Included | Included |
| Bayesian optimal design for multiple efficacy endpoints | Not included | Included | Included |
| Bayesian optimal design for nested efficacy endpoints | Not included | Included | Included |
| Bayesian optimal design for continuous endpoints | Not included | Included | Included |
| Bayesian optimal design for time-to-event endpoints | Not included | Included | Included |
| rBOP2Randomized | Not included | Included | Included |
| Information borrowingHistorical data | Not included | Not included | Included |
| KM curve reconstructionIndividual patient data | Not included | Not included | Included |
| Phase IIIConfirmatory | |||
| Confirmatory designsComing soon | |||
| Trial monitoringOngoing trials | |||
| Monitoring toolsComing soon | |||
| Seats and support | |||
| Simulations | Limited | Unlimited | Unlimited |
| Seats | 1 | Per seat | Unlimited |
| Priority support | Not included | Included | Included |